DDIT3 and diffuse large B-cell lymphoma: In our study, the CR rates of DE-DLBCL patients with p53 expression >50% and p53 expression ≤50%, treated with R-CHOP, were 11.1% and 58.7% (P= 0.025), and the 1-year PFS rates were 55.6% and 74.8% (P= 0.00054), respectively.